#RussiaCancerVaccine #HeadlineNews #YTCancerNews #CancerResearch2025 #BiotechNews #MedicalNewsToday

Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), made the announcement on Saturday at the Eastern Economic Forum (EEF) in Vladivostok, according to a report by Russian news agency TASS.

"The research spanned several years, with the last three dedicated to mandatory preclinical studies," Skvortsova reportedly said. "The vaccine is now ready for use; we are awaiting official approval."

Skvortsova is said to have emphasized that preclinical results confirmed the vaccine's safety, even with repeated administration, and significant effectiveness.

Cancer and vaccine therapy 3D illustration. Rasi Bhadramani/Getty Images
Cancer and vaccine therapy 3D illustration. Rasi Bhadramani/Getty Images
© Rasi Bhadramani/Getty Images
Researchers observed reductions in tumor size and slowed tumor progression—ranging from 60 to 80 percent—depending on disease characteristics. Studies also indicated increased survival rates attributable to the vaccine.

Various media reports also suggest that the vaccine has shown 100 percent efficacy in preclinical trials, although Newsweek has been unable to verify this claim.

The initial target for the vaccine will be colorectal cancer, according to the TASS report.

Видео #RussiaCancerVaccine #HeadlineNews #YTCancerNews #CancerResearch2025 #BiotechNews #MedicalNewsToday канала Headline News